1. The Royal Australian College of General Practitioners and Osteoporosis Australia. Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age, 2nd edn.  East Melbourne, Vic: RACGP,2017.
  2. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Technical Report Series, no. 843. Geneva: WHO, 1994.
  3. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopaenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165-2174.
  4. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S healthcare system. J Clin Endocrinol Metab. 2008;93:3499-3504.
  5. Lachatre M, Pasquet A, Ajana F, et al. HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy. AIDS 2017;31:451-453.
  6. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937-946.
  7. Shiau S, BrounEC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS. 2013;27:1949-1957.
  8. Carr A, Hoy J. Low bone mineral density with tenofovir: does statistically significant mean clinically significant? Clin Infect Dis. 2010;51:973-975.
  9. Brown TT, Hoy J, Borderi M, et al. Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis. 2015;60:1242-1251.
  10. 10.Malgo F, Appelman-Dijsktra NM, Ternatt MF, et al. High prevalence of secondary factors for bone fragility in patients with a recent fracture independently of BMD. Arch Osteoporosis 2016;11;12. Doi:10.1007/s11657-016-0258-3.
  11. Society EAC. Clinical management and treatment of HIV-infected adults in Europe. Available at: http:// Accessed 12 th September.
  12. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV infection: two randomised, double-blind,non-inferiority trials. Lancet. 2015;385:2606-2615.
  13. Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention
  14. of HIV infection in adults: 2018 recommendations of the International
  15. Antiviral Society–USA Panel. JAMA. 2018;320:379-396.
  16. Department of health and Ageing and national health and medical Research Council. Nutrient reference values for Australia and new Zealand. Canberra, ACT: doHA and NHMRC, 2006.
  17. Panel on Prevention of Falls in Older Persons, American Geriatrics Society, British Geriatrics Society. Summary of the updated American Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. J Am Geriatr
  18. Soc 2011;59:148–157.
  19. Australian Commission on Safety and Quality in Health Care. Preventing falls and harm from falls in older people: Best practice guidelines for Australian hospitals, residential aged care facilities and community care. Darlinghurst, NSW: ACSQHC, 2009. Available at [Accessed 13 September 2018].
  20. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium
  21. and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007;21:2473–2482.
  22. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded,
  23. randomized controlled trial of zoledronate therapy for HIV-associated
  24. osteopenia and osteoporosis. AIDS 2009; 23:51–7.
  25. Bolland MJ, Grey AB, Horne AM, et al. Effects of intravenous zoledronate
  26. on bone turnover and bone density persist for at least five years in
  27. HIV-infected men. J Clin Endocrinol Metab 2012; 97:1922–8.
  28. Rozenberg S, Lanoy E, Bentata M, et al. Effect of alendronate on
  29. HIV-associated osteoporosis: a randomized, double-blind, placebocontrolled,
  30. 96-week trial (ANRS 120). AIDS Res Hum Retroviruses 2012; 28:972–9.
  31. Ofotokun I, Titanji K, Lahiri CD, et al. A single-dose zoledronic acid infusion prevents antiretroviral therapy-induced bone loss in treatment-naïve HIV-infected patients: A phase 11b trial. Clin Infect Dis 2016;63:633-671.
  32. Hoy JF, Richardson R, Ebeling PR, et al. Zolendronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV. AIDS 2018;32:1967-1975.
  33. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29(1):1–23.
  34. Mateo L, Holgato S, Marinoso ML, et a. Hypophosphataemic osteomalacia induced by tenofovir in HIV-infected patients. Clin Rheumatol 2016;35:1271-1279.
  35. Borderi M, Gibellini D, Vescini F, et al.Metabolic bone disease in HIV infection.AIDS 2009;23:1297-1310.
  36. Morse CG, Mican JM, Jones EC, et al.The incidence and natural history of osteonecrosis in HIV-infected adults. Clin Infect Dis 2007;44:739-748.
  37. Brown P, Crane L. Avascular necrosis of bone in patients with human immunodeficiency virus infection:report of 6 cases and review of the literature. Clin Infect Dis 2001;32:1221-1226.
  38. Brown TT, Moser C, Currier JS, et al. Changes in bone mineral density after initiation of antiretroviral treatment with tenofovir disoproxil fumerate/emtricitabine plus atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. J Infect Dis 2015;212:1241-1249.
  39. Borges AH, Hoy J, Florence E, et al. Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort. Clin Infect Dis 2017;64:1413-1421.
  40. Permpalung N, Ungprasert P, Summachiwacki S, et al. Protease inhibitors and avascular necrosis: a systematic review and met-analysis. Int J Antimicrob Agents 2014;44:93-95.
  41. Lawson-Avayi S, Bonnet F,Bernardin E, et al. Avascular necrosis in HIV-infected patients: a case-control study from the Aquitine Cohort, 1997-2002, France. Clin Infect Dis 2005;40:1188-1193.
  42. Mazzotta E, Agostinone A, Rosso R, et al. Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study. J Bone miner Metab 2011;29:383-388.
  43. 33.Bayard C, Ledergerber B, Flepp M, et al. Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. Open Forum Infectious Diseases. 2017;4(4):ofx177. doi:10.1093/ofid/ofx177.
  44. Dolutegravir. In Australian Medicines Handbook 2018 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2018 July. Available from:
  45. Raffi F, Orkin C, Clarke A, et al. Long-term (96-Week) efficacy and safety after switching
  46. from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically
  47. suppressed adults. J Acquir Immune Defic Syndr 2017;75:226-231.
  48. Hoy JF, Grund B, Roediger M, et al. Immediate initiation of antiretroviral therapy for HIV
  49. infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial. J Bone Miner Res 2017;32:1945-1955.
  50. Dong HV, Cortes YI, Shiau S, et al. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis. AIDS. 2014;28:2119-2131.
  51. Hileman CO, Ross Eckard A, McComsey GA. Bone loss in HIV – a contemporary review. Curr Opin Endocrinol Obes 2015;22:446-451.
  52. Erlandson KM, Jiang Y, Debanne SM, et al. Effects of randomised rosuvastatin compared with placebo on bone and body composition among HIV-infected adults. AIDS 2015;29:175-182.
  53. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One 2011;6:e23688.
  54. Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One 2014;9:e90111.
  55. Mulligan K, Glidden DV, Anderson PI, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomised, double-blind, placebo-controlled trail: dual-energy X-ray absorptiometry results from iPrEx. Clin Infect Dis 2015; 61:572-580.
  56. Morse CG, Mican JM, Jones EC, et al. The incidence and natural history of osteonecrosis in HIV-infected adults. Clin Infect Dis 2007;739-748.
  57. Puthanakit T, Siberry G. Bone health in children and adolescents with perinatal HIV infection. J Int AIDS Soc 2013; 16:18575
  58. Yin MT, Brown TT. HIV and bone complications:understudied populations and new management strategies. Curr HIV/AIDS Rep 2016;13:349-358
  59. WHO. 2016. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Available at: (accessed September 2018).
  60. Gallant J, Hsue PY, Shreay S, et al. Comorbidities among US patients with prevalent HIV infection- a trend analysis. J Infect Dis 2017;2016:1525-1533.
  61. Barlow-Mosha L, Ross Eckard A, McComsey GA, et al. Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc 2013;16:18600.
  62. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 36:756–765.
  63. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43:222-229.
  64. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 2017;32:1291-1296.
  65. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 2016;16:43-52.
  66. Gutierrez F, Masia M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev 2011;13:109-118.
  67. Beaupere C, Garcia M, larghero J, et al. The HIV proteins Tat and Nef promote human bone marrow mesenchymal stem cell senescence and alter osteoblastic differentiation. Aging cell 2015;14:534-546.
  68. Ajmal M, Cheng EY. Biological factors influencing osteonecrosis: steroids, statins, ethanol, Human Immunodeficiency Virus and antiretroviral therapy, and smoking. Semin Arthro. 2007;18:180-183.
  69. Allison GT, Bostrom MP, Glesby MJ. Osteonecrosis in HIV disease: epidemiology, etiologies, and clinical management. AIDS 2003;17:1-9.
  70. Morse CG, Dodd LE, Nghiem K, et al. Elevations in D-dimer and C-reactive protein are associated with the development of osteonecrosis of the hip in HIV-infected adults. AIDS 2013;27:591-595.
  71. Mary-Krause M, Billaud E, Poizot-Martin I, et al. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS 2006;20:1627-1635.
  72. Mazzotta E, Agostinone A, Rosso R, et al. Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study. J bone Miner Metab 2011;20:383-388.
  73. Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002;137:17-24.